Perrigo Company plc (PRGO) announced the FDA has rescheduled a joint meeting of the Nonprescription Drugs Advisory Committee and the Obstetrics, Reproductive, and Urologic Drugs Advisory Committee for May 9 & 10, 2023, to review the company's application for Opill daily oral contraceptive for over-the-counter use.
Last year, the company's HRA Pharma affiliate filed an application with the FDA for the Rx-to-OTC switch of Opill, a progestin-only daily birth control pill.
The company noted that, if approved, Opill would be the first ever daily birth control pill available OTC, without a prescription, in the U.S.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News